Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Sofosbuvir und Velpatasvir, ATC J05AP55 für die Zeit 01.05.26-30.04.28

Section 130a (8) of the German Social Code V (SGB V) enables health insurance funds and pharmaceutical companies to conclude framework discount contracts for medicines to be dispensed at the expense of the statutory health insurance funds. With regard to the relevant legal provisions for the award of public contracts, a regular process of substance-related, formal tendering procedures according to the regulations of Part 4 of the German Act Against Restraints of Competition (GWB) is carried out by DAK-Gesundheit. For medicines to be specified by the bidder in more detail in Annex 2 to the contract, containing the aforementioned active substances Sofosbuvir and Velpatasvir, ATC J05AP55, DAK-Gesundheit intends to conclude medicines discount contracts with as many interested pharmaceutical companies as possible until the entry into force of new medicines discount contracts. A discount contract under the licensing model for the aforementioned active substance comes into force for the first time on 01.05.2026 and ends on 30.04.2028. It ends automatically with the entry into force of the Exclusive Contract, regardless.